PALATIN TECHNOLOGIES INC (PTN)

US6960775020 - Common Stock

0.9679  +0.11 (+12.55%)

After market: 1.04 +0.07 (+7.45%)

Fundamental Rating

2

PTN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. PTN may be in some trouble as it scores bad on both profitability and health. PTN is not valued too expensively and it also shows a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PTN has reported negative net income.
In the past year PTN has reported a negative cash flow from operations.
PTN had negative earnings in each of the past 5 years.
PTN had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -947.33%, PTN is doing worse than 99.12% of the companies in the same industry.
Industry RankSector Rank
ROA -947.33%
ROE N/A
ROIC N/A
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PTN's Gross Margin of 184.24% is amongst the best of the industry. PTN outperforms 99.29% of its industry peers.
In the last couple of years the Gross Margin of PTN has declined.
PTN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 184.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

PTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTN has been increased compared to 1 year ago.
The number of shares outstanding for PTN has been increased compared to 5 years ago.
PTN has a better debt/assets ratio than last year.

2.2 Solvency

PTN has an Altman-Z score of -216.09. This is a bad value and indicates that PTN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PTN (-216.09) is worse than 98.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -216.09
ROIC/WACCN/A
WACC11.94%

2.3 Liquidity

PTN has a Current Ratio of 0.26. This is a bad value and indicates that PTN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of PTN (0.26) is worse than 95.93% of its industry peers.
A Quick Ratio of 0.26 indicates that PTN may have some problems paying its short term obligations.
The Quick ratio of PTN (0.26) is worse than 95.40% of its industry peers.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.26

More info and screens

4

3. Growth

3.1 Past

PTN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.91%.
The Revenue for PTN has decreased by -60.92% in the past year. This is quite bad
PTN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.52% yearly.
EPS 1Y (TTM)7.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)-60.92%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PTN will show a very strong growth in Earnings Per Share. The EPS will grow by 30.24% on average per year.
The Revenue is expected to grow by 162.67% on average over the next years. This is a very strong growth
EPS Next Y0.95%
EPS Next 2Y52.7%
EPS Next 3Y48.26%
EPS Next 5Y30.24%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

PTN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 1.41, which indicates a rather cheap valuation of PTN.
99.65% of the companies in the same industry are more expensive than PTN, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.83, PTN is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.41

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PTN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PTN's earnings are expected to grow with 48.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.7%
EPS Next 3Y48.26%

More info and screens

0

5. Dividend

5.1 Amount

PTN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALATIN TECHNOLOGIES INC

NYSEARCA:PTN (12/20/2024, 8:04:01 PM)

After market: 1.04 +0.07 (+7.45%)

0.9679

+0.11 (+12.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)02-13 2025-02-13/bmo
Inst Owners14.88%
Inst Owner Change-44.93%
Ins Owners0.96%
Ins Owner Change12.57%
Market Cap18.92M
Analysts80
Price Target17.34 (1691.51%)
Short Float %5.38%
Short Ratio3.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.54%
Min EPS beat(2)10.8%
Max EPS beat(2)24.29%
EPS beat(4)2
Avg EPS beat(4)-35.81%
Min EPS beat(4)-172.69%
Max EPS beat(4)24.29%
EPS beat(8)3
Avg EPS beat(8)-24.81%
EPS beat(12)5
Avg EPS beat(12)-21.17%
EPS beat(16)7
Avg EPS beat(16)-25%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)96.15%
EPS NQ rev (1m)-61.54%
EPS NQ rev (3m)-61.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-72.03%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.41
P/S 7.94
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)0.69
Fwd EY70.96%
FCF(TTM)-1.67
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0.12
BVpS-0.39
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -947.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 184.24%
FCFM N/A
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
F-Score3
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.26
Altman-Z -216.09
F-Score3
WACC11.94%
ROIC/WACCN/A
Cap/Depr(3y)120.27%
Cap/Depr(5y)96.16%
Cap/Sales(3y)9.17%
Cap/Sales(5y)16.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y0.95%
EPS Next 2Y52.7%
EPS Next 3Y48.26%
EPS Next 5Y30.24%
Revenue 1Y (TTM)-60.92%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%
EBIT growth 1Y-3.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.48%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.52%
OCF growth 3YN/A
OCF growth 5YN/A